No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences, Inc. | 1.19B | 40.75 | 65.73 | 51.09% | -3.56% | -2.62% | 3.07% | 0.06 |
| MYNZMainz Biomed B.V. | 10.78M | 1.19 | -0.05 | -0.17% | -24.92% | -6.63% | 0.54 | |
| BNRBurning Rock Biotech Limited | 301.02M | 33.32 | -0.99 | -4.02% | -22.48% | -22.06% | 0.09 | |
| MDXHMDxHealth S.A. | 190.56M | 3.71 | -3.20 | 28.29% | -40.43% | -345.31% | 4.05 | |
| PSNLPersonalis, Inc. | 853.41M | 9.61 | -7.01 | 15.15% | -106.92% | -43.1% | 0.22 | |
| EXASExact Sciences Corporation | 19.44B | 102.34 | -18.31 | 10.37% | -32.01% | -39.44% | 0.38% | 1.15 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 13.75M | 22.79M | 51.87M | 62.65M | 94.08M | 137.04M | 219.79M | 332.07M |
| Revenue Growth % | - | 0.66% | 1.28% | 0.21% | 0.5% | 0.46% | 0.6% | 0.51% |
| Cost of Goods Sold | 4.92M | 5.3M | 7.31M | 9.69M | 15.82M | 32.01M | 44.98M | 60.2M |
| COGS % of Revenue | 0.36% | 0.23% | 0.14% | 0.15% | 0.17% | 0.23% | 0.2% | 0.18% |
| Gross Profit | 8.83M | 17.49M | 44.55M | 52.96M | 78.26M | 105.03M | 174.81M | 271.86M |
| Gross Margin % | 0.64% | 0.77% | 0.86% | 0.85% | 0.83% | 0.77% | 0.8% | 0.82% |
| Gross Profit Growth % | - | 0.98% | 1.55% | 0.19% | 0.48% | 0.34% | 0.66% | 0.56% |
| Operating Expenses | 19.73M | 21.32M | 37.23M | 59.51M | 118.34M | 177.88M | 242.78M | 263.19M |
| OpEx % of Revenue | 1.43% | 0.94% | 0.72% | 0.95% | 1.26% | 1.3% | 1.1% | 0.79% |
| Selling, General & Admin | 15.26M | 16.47M | 29.84M | 48.13M | 86.74M | 143M | 180.15M | 200.05M |
| SG&A % of Revenue | 1.11% | 0.72% | 0.58% | 0.77% | 0.92% | 1.04% | 0.82% | 0.6% |
| Research & Development | 4.47M | 4.85M | 7.38M | 13.26M | 29.65M | 44.9M | 53.62M | 52.04M |
| R&D % of Revenue | 0.33% | 0.21% | 0.14% | 0.21% | 0.32% | 0.33% | 0.24% | 0.16% |
| Other Operating Expenses | 163.29K | 0 | 0 | -1.88M | 1.96M | -10.02M | 9.01M | 11.11M |
| Operating Income | -10.9M | -3.84M | 7.33M | -6.54M | -40.08M | -72.86M | -67.98M | 8.67M |
| Operating Margin % | -0.79% | -0.17% | 0.14% | -0.1% | -0.43% | -0.53% | -0.31% | 0.03% |
| Operating Income Growth % | - | 0.65% | 2.91% | -1.89% | -5.13% | -0.82% | 0.07% | 1.13% |
| EBITDA | -10.59M | -3.51M | 7.69M | -6.07M | -36.67M | -62.31M | -55.65M | 24.67M |
| EBITDA Margin % | -0.77% | -0.15% | 0.15% | -0.1% | -0.39% | -0.45% | -0.25% | 0.07% |
| EBITDA Growth % | - | 0.67% | 3.19% | -1.79% | -5.04% | -0.7% | 0.11% | 1.44% |
| D&A (Non-Cash Add-back) | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M |
| EBIT | -10.71M | -4.08M | 9.92M | -7.57M | -40.01M | -68.89M | -57.35M | 22.14M |
| Net Interest Income | -1.62M | -2.25M | -4.26M | -2.26M | 67K | 3.95M | 10.61M | 12.34M |
| Interest Income | 26.18K | 23.51K | 312K | 373K | 68K | 3.97M | 10.62M | 12.92M |
| Interest Expense | 1.65M | 2.27M | 4.57M | 2.63M | 1K | 17K | 11K | 577K |
| Other Income/Expense | -1.46M | -2.52M | -1.98M | -3.66M | 67K | 3.95M | 10.61M | 12.89M |
| Pretax Income | -12.36M | -6.36M | 5.35M | -10.2M | -40.01M | -68.9M | -57.37M | 21.56M |
| Pretax Margin % | -0.9% | -0.28% | 0.1% | -0.16% | -0.43% | -0.5% | -0.26% | 0.06% |
| Income Tax | 9.73K | 8.61K | 72K | 84K | -8.72M | -1.77M | 101K | 3.32M |
| Effective Tax Rate % | 1% | 1% | 0.99% | 1.01% | 0.78% | 0.97% | 1% | 0.85% |
| Net Income | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M |
| Net Margin % | -0.9% | -0.28% | 0.1% | -0.16% | -0.33% | -0.49% | -0.26% | 0.05% |
| Net Income Growth % | - | 0.49% | 1.83% | -2.95% | -2.04% | -1.15% | 0.14% | 1.32% |
| Net Income (Continuing) | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.26 | -0.60 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 |
| EPS Growth % | - | 0.52% | 0.65% | -1.57% | -1.3% | -1.08% | 0.17% | 1.29% |
| EPS (Basic) | -1.26 | -0.60 | 0.35 | -0.54 | -1.24 | -2.58 | -2.14 | 0.66 |
| Diluted Shares Outstanding | 9.78M | 10.65M | 8.66M | 18.93M | 25.14M | 26.05M | 26.8M | 29.25M |
| Basic Shares Outstanding | 9.78M | 10.65M | 8.58M | 18.93M | 25.14M | 26.05M | 26.8M | 27.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.68M | 18.13M | 116.68M | 429.59M | 353.74M | 292.29M | 295.63M | 360.15M |
| Cash & Short-Term Investments | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 258.63M | 243.1M | 293.13M |
| Cash Only | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 122.95M | 98.84M | 119.71M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 135.68M | 144.26M | 173.42M |
| Accounts Receivable | 4.65M | 12.09M | 14.65M | 12.76M | 17.28M | 23.48M | 38.3M | 51.22M |
| Days Sales Outstanding | 123.46 | 193.67 | 103.09 | 74.34 | 67.05 | 62.53 | 63.61 | 56.3 |
| Inventory | 304.58K | 882.23K | 1.24M | 2.22M | 2.02M | 3.98M | 7.94M | 8.13M |
| Days Inventory Outstanding | 22.59 | 60.79 | 61.77 | 83.55 | 46.62 | 45.38 | 64.44 | 49.32 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 6.21M | 6.29M | 7.67M |
| Total Non-Current Assets | 3.14M | 4.28M | 3.06M | 9.73M | 108.83M | 155.04M | 157.71M | 171.08M |
| Property, Plant & Equipment | 1.47M | 1.53M | 2.06M | 7.1M | 16.88M | 26.5M | 37.74M | 62.71M |
| Fixed Asset Turnover | 9.36x | 14.90x | 25.18x | 8.82x | 5.57x | 5.17x | 5.82x | 5.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 10.69M | 10.69M | 10.69M |
| Intangible Assets | 40.12K | 4.17K | 0 | 0 | 88.92M | 115.66M | 106.64M | 95.54M |
| Long-Term Investments | 1.56M | 2.53M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.63M | 2.75M | 1M | 2.63M | 3.02M | 2.2M | 2.63M | 2.15M |
| Total Assets | 9.82M | 22.4M | 119.75M | 439.33M | 462.57M | 447.33M | 453.34M | 531.24M |
| Asset Turnover | 1.40x | 1.02x | 0.43x | 0.14x | 0.20x | 0.31x | 0.48x | 0.63x |
| Asset Growth % | - | 1.28% | 4.34% | 2.67% | 0.05% | -0.03% | 0.01% | 0.17% |
| Total Current Liabilities | 5.22M | 6.74M | 15.29M | 20.88M | 24.89M | 36.13M | 47.67M | 49.39M |
| Accounts Payable | 1.12M | 1.45M | 1.86M | 2.1M | 2.55M | 4.73M | 10.27M | 6.9M |
| Days Payables Outstanding | 82.82 | 99.99 | 93.12 | 79.07 | 58.73 | 53.95 | 83.32 | 41.84 |
| Short-Term Debt | 1M | 0 | 5.83M | 0 | 0 | 0 | 0 | 278K |
| Deferred Revenue (Current) | 9.73K | 0 | 0 | 1000K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 706.64K | 6M | 10M | 16.91M | 25.67M | 30.69M | 774K |
| Current Ratio | 1.28x | 2.69x | 7.63x | 20.58x | 14.21x | 8.09x | 6.20x | 7.29x |
| Quick Ratio | 1.22x | 2.56x | 7.55x | 20.47x | 14.13x | 7.98x | 6.04x | 7.13x |
| Cash Conversion Cycle | 63.23 | 154.47 | 71.73 | 78.82 | 54.93 | 53.96 | 44.73 | 63.78 |
| Total Non-Current Liabilities | 18.87M | 25.74M | 19.34M | 2.76M | 25.95M | 12.05M | 14.4M | 26.01M |
| Long-Term Debt | 17.6M | 24.5M | 19.29M | 0 | 0 | 0 | 0 | 9.74M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 7.02M | 11.62M | 14.2M | 14.66M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 635K | 428K | 206K | 1.61M |
| Other Non-Current Liabilities | 1.27M | 1.24M | 55K | 1.03M | 18.29M | 0 | 0 | 0 |
| Total Liabilities | 24.09M | 32.47M | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M | 75.4M |
| Total Debt | 18.6M | 24.5M | 25.12M | 0 | 8.2M | 13.4M | 15.34M | 26.34M |
| Net Debt | 17.39M | 20.02M | -73.72M | -409.85M | -321.43M | -109.55M | -83.51M | -93.36M |
| Debt / Equity | - | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x |
| Debt / EBITDA | - | - | 3.27x | - | - | - | - | 1.07x |
| Net Debt / EBITDA | - | - | -9.59x | - | - | - | - | -3.79x |
| Interest Coverage | -6.61x | -1.69x | 1.60x | -2.48x | -40079.00x | -4285.59x | -6179.73x | 15.03x |
| Total Equity | -14.27M | -10.07M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.83M |
| Equity Growth % | - | 0.29% | 9.45% | 3.88% | -0.01% | -0.03% | -0.02% | 0.17% |
| Book Value per Share | -1.46 | -0.95 | 9.83 | 21.96 | 16.38 | 15.32 | 14.60 | 15.58 |
| Total Shareholders' Equity | -14.27M | -10.07M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.83M |
| Common Stock | 1.9K | 1.92K | 17K | 25K | 25K | 27K | 27K | 28K |
| Retained Earnings | -51.12M | -57.49M | -52.21M | -62.5M | -93.77M | -160.91M | -218.37M | -200.13M |
| Treasury Stock | -809.6K | -2.42M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -638.47K | -909.38K | 0 | 0 | 0 | -381K | 136K | 230K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.23M | -12.29M | 7.01M | 9.87M | -18.98M | -41.66M | -5.63M | 64.87M |
| Operating CF Margin % | -0.89% | -0.54% | 0.14% | 0.16% | -0.2% | -0.3% | -0.03% | 0.2% |
| Operating CF Growth % | - | -0% | 1.57% | 0.41% | -2.92% | -1.19% | 0.86% | 12.53% |
| Net Income | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M |
| Depreciation & Amortization | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M |
| Stock-Based Compensation | 108.7K | 293.64K | 1.25M | 8.31M | 21.74M | 36.32M | 51.22M | 50.32M |
| Deferred Taxes | -163.29K | 272.42K | -2.28M | 0 | -8.74M | -1.88M | -223K | 1.4M |
| Other Non-Cash Items | 520.23K | 542.37K | 2.37M | 2.22M | 0 | -19.5M | -4.86M | -6.97M |
| Working Capital Changes | -640.51K | -7.36M | 44K | 9.15M | -4.1M | -7K | -6.63M | -14.13M |
| Change in Receivables | -428.21K | -8.41M | -896K | 1.66M | -4.63M | -6.22M | -14.93M | -12.64M |
| Change in Inventory | -115.56K | -577.66K | -355K | -980K | 327K | -1.68M | -3.96M | -193K |
| Change in Payables | 370.9K | 197.25K | 557K | 169K | -182K | 582K | 5.71M | -4.37M |
| Cash from Investing | -494.85K | -277.04K | -937K | -4.75M | -66.66M | -166.54M | -16.18M | -50.14M |
| Capital Expenditures | -494.85K | -277.04K | -937K | -4.75M | -3.48M | -5.63M | -13.62M | -28.33M |
| CapEx % of Revenue | 0.04% | 0.01% | 0.02% | 0.08% | 0.04% | 0.04% | 0.06% | 0.09% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 3K | -63.17M | 742K | 13K | 0 |
| Cash from Financing | 8.87M | 15.84M | 88.29M | 305.89M | 5.42M | 1.51M | -2.3M | 6.14M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 3.55K | 0 | 1.39M | 3.21M | 5.43M | 1.64M | -2.16M | -5.78M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -12.73M | -12.57M | 6.08M | 5.11M | -22.47M | -47.29M | -19.25M | 36.54M |
| FCF Margin % | -0.93% | -0.55% | 0.12% | 0.08% | -0.24% | -0.35% | -0.09% | 0.11% |
| FCF Growth % | - | 0.01% | 1.48% | -0.16% | -5.39% | -1.1% | 0.59% | 2.9% |
| FCF per Share | -1.30 | -1.18 | 0.70 | 0.27 | -0.89 | -1.81 | -0.72 | 1.25 |
| FCF Conversion (FCF/Net Income) | 0.99x | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x |
| Interest Paid | 0 | 1.64M | 2.21M | 1.98M | 1K | 16K | 11K | 434K |
| Taxes Paid | 0 | 160K | 150K | 102K | 16K | 120K | 198K | 2.5M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | 14.06% | -4.11% | -7.56% | -16.56% | -14.54% | 4.31% |
| Return on Invested Capital (ROIC) | -262.06% | -44.02% | 51.5% | -56.96% | -62.53% | -28.77% | -17.07% | 1.94% |
| Gross Margin | 64.21% | 76.75% | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | 81.87% |
| Net Margin | -89.93% | -27.94% | 10.17% | -16.42% | -33.26% | -48.99% | -26.15% | 5.49% |
| Debt / Equity | - | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x |
| Interest Coverage | -6.61x | -1.69x | 1.60x | -2.48x | -40079.00x | -4285.59x | -6179.73x | 15.03x |
| FCF Conversion | 0.99x | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x |
| Revenue Growth | - | 65.67% | 127.62% | 20.79% | 50.18% | 45.65% | 60.38% | 51.09% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Dermatologic | 85.75M | 124.81M | 183.38M | 257M |
| Dermatologic Growth | - | 45.54% | 46.92% | 40.15% |
| Service, Other | 8.33M | 12.23M | - | - |
| Service, Other Growth | - | 46.78% | - | - |
Castle Biosciences, Inc. (CSTL) has a price-to-earnings (P/E) ratio of 65.7x. This suggests investors expect higher future growth.
Castle Biosciences, Inc. (CSTL) reported $343.5M in revenue for fiscal year 2024. This represents a 2398% increase from $13.8M in 2017.
Castle Biosciences, Inc. (CSTL) grew revenue by 51.1% over the past year. This is strong growth.
Castle Biosciences, Inc. (CSTL) reported a net loss of $12.2M for fiscal year 2024.
Castle Biosciences, Inc. (CSTL) has a return on equity (ROE) of 4.3%. This is below average, suggesting room for improvement.
Castle Biosciences, Inc. (CSTL) generated $25.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.